Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage
OCEANSIDE, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data demonstrating the ability of its NeuroStilbene intranasal formulation of pterostilbene to successfully prevent the development of brain injury in an animal model of Chronic Traumatic Encephalopathy.
Through a collaboration with its Scientific Advisory Board Member Dr. Santosh Kesari, and NFL Chargers Hall of Famer Wes Chandler, the Company has filed a patent covering these new findings and means of utilizing pterostilbene based formulations for prevention and treatment of Chronic Traumatic Encephalopathy.
"The current data provided in the patent strongly supports the possibility that receiving NeuroStilbene before sports-related brain injuries will prevent the development of Chronic Traumatic Encephalopathy," said Wes Chandler, Chairman of the TSOI CTE Advisory Board. "As someone who personally suffers from Chronic Traumatic Encephalopathy, including depression, memory loss, hand tremors, and a loss even of my penmanship, I can speak first hand on the urgent need to provide players with medical solutions to prevent the development of CTE. It is our intention to add additional athletes who suffer from similar types of ailments from all sports and not just football to the CTE Advisory Board. This is not about abolishing professional sports entities, but an attempt to collaborate for prevention and treatment of this terrible condition."
Chronic Traumatic Encephalopathy is a major problem in football, other contact sports, and military veterans. This condition has been seen in people as young as 17, but symptoms do not generally begin appearing until years after the onset of head impacts. Common symptoms of Chronic Traumatic Encephalopathy in the early stages of the condition include impulse control problems, aggression, depression, and paranoia. As the disease progresses, some patients may experience problems with thinking and memory, including memory loss, confusion, impaired judgment, and eventually progresses to dementia.
"NeuroStilbene is a nanotechnology-based formulation of pterostilbene which is produced from naturally occurring ingredients and is currently available for purchase as a nutraceutical. Although our recent data demonstrates a reduction in tau and suppression of brain cell damage with NeuroStilbene, clinical trials are needed before specific medical claims can be made," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Vice Chairman of the CTE Advisory Board. "That being said, there are numerous peer reviewed scientific publications showing pterostilbene protects against brain damage in a variety of settings. For example, some studies show pterostilbene suppresses inflammation associated memory decline [1,2], other studies show pterostilbene suppresses hemorrhagic brain injury and neuronal cell death[3,4] and yet other ones show protection of the brain against damage associated with lack of oxygen and aging[5,6,7]. Given all this supporting data, it is a logical extension to believe that NeuroStilbene, which is a more potent formulation of pterostilbene, would possess activity against Chronic Traumatic Encephalopathy."
Previous clinical studies by the Company have demonstrated that NanoStilbene possesses superior distribution and half-life of pterostilbene when administered to healthy volunteers.
"The filing of today's patent represents a successful collaboration between medical, basic research, and sports experts," said Timothy Dixon, President, and CEO of TSOI. "It is our honor to work with experts such as Dr. Kesari who understand not only the basic science of how the healthy and diseased brain works but also possess the medical insight to translate findings into patients."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com.
1. Naik et al. Pterostilbene ameliorates intracerebroventricular streptozotocin induced memory decline in rats.
Cogn Neurodyn. 2017 Feb;11(1):35-49. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264756/
2. Hou et al. Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:92-102. https://www.ncbi.nlm.nih.gov/pubmed/24709550
3. Liu et al. Pterostilbene Attenuates Early Brain Injury Following Subarachnoid Hemorrhage via Inhibition of the NLRP3 Inflammasome and Nox2-Related Oxidative Stress. Mol Neurobiol. 2017 Oct;54(8):5928-5940. https://www.ncbi.nlm.nih.gov/pubmed/27665283
4. Wang et al. Neuroprotective effects of pterostilbene against oxidative stress injury: Involvement of nuclear factor erythroid 2-related factor 2 pathway. Brain Res. 2016 Jul 15;1643:70-9. https://www.ncbi.nlm.nih.gov/pubmed/27107941
5. Chang et al. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging. 2012 Sep;33(9):2062-71. https://www.ncbi.nlm.nih.gov/pubmed/21982274
6. Cherniack et al. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br J Nutr. 2012 Sep;108(5):794-800. https://www.ncbi.nlm.nih.gov/pubmed/22475317
7. Yang et al. HO-1 Signaling Activation by Pterostilbene Treatment Attenuates Mitochondrial Oxidative Damage Induced by Cerebral Ischemia Reperfusion Injury. Mol Neurobiol. 2016 May;53(4):2339-53. https://www.ncbi.nlm.nih.gov/pubmed/25983033
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com